slide1
Download
Skip this Video
Download Presentation
Philip A Kalra Lead Nephrologist for ASTRAL, Hope Hospital, Salford, UK, On behalf of the ASTRAL TMC and collaborators

Loading in 2 Seconds...

play fullscreen
1 / 18

Trial Overview - PowerPoint PPT Presentation


  • 100 Views
  • Uploaded on

UK MULTI-CENTRE TRIAL IN ATHEROSCLEROTIC RENOVASCULAR DISEASE ASTRAL A ngioplasty and ST ent for R enal A rtery L esions. Philip A Kalra Lead Nephrologist for ASTRAL, Hope Hospital, Salford, UK, On behalf of the ASTRAL TMC and collaborators. ASTRAL Trial Schema.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Trial Overview' - benjamin


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

UK MULTI-CENTRE TRIAL IN ATHEROSCLEROTIC RENOVASCULAR DISEASE

  • ASTRAL
  • Angioplasty and STent for Renal Artery Lesions

Philip A Kalra

Lead Nephrologist for ASTRAL, Hope Hospital, Salford, UK,

On behalf of the ASTRAL TMC and collaborators

slide2

ASTRAL Trial Schema

No revascularisationMedical Treatment only

Revascularisation

with angioplasty and/or stent

(and medical treatment)

Diagnosis of ARVD (Unilateral or Bilateral)Revascularisation not contraindicated

Uncertain whether to revasculariseRandomisation

safety immediate post op complications
SAFETY – IMMEDIATE POST-OP COMPLICATIONS
  • 24 patients experienced an immediate post-op complication
    • Revascularisation = 23 / 308 (7%)
    • Medical = 1 / 18 (6%)
  • Most patients (88%) had one complication
mean change in scr between baseline and 1 year
MEAN CHANGE IN SCr BETWEEN BASELINE AND 1 YEAR

Negative change = Improvement in SCr (i.e. reduction in SCr)

slide15
TIME TO FIRST OF MI, STROKE, VASCULAR DEATH OR HOSPITALISATION FOR ANGINA, FLUID OVERLOAD OR CARDIAC FAILURE

HR=0.90, 95% CI=0.66 to 1.15

mortality
MORTALITY

HR=0.92, 95% CI=0.68 to 1.26

summary
SUMMARY
  • Currently no evidence of a benefit for revascularisation on renal function in the ARVD patients entered into ASTRAL – those in whom clinicians ‘uncertain’ of whether to revascularise
  • Also no evidence of differences between the arms for any of the secondary endpoints (i.e. blood pressure, major events)
  • No evidence of differences in treatment effect across the various subgroups
  • Longer follow-up is needed
  • Plan to update meta-analysis published in NDT in 2003 to include ASTRAL and other trials
ad